About
IASO Bio develops cell therapies and biologics for hematologic malignancies and autoimmune diseases. It operates in Nanjing, Shanghai, and Pleasanton, with global R&D, clinical, and manufacturing activities spanning discovery through commercialization.
Iasobio is a CRDMO in Nanjing, China, founded in 2017. It lists 9 services, including Fully Human Antibody Discovery Platform, High-throughput CAR-T Cell Therapy Screening and Optimization Platform and In Vivo CAR-T Platform. It names GMP on its listing.
Services
Fully Human Antibody Discovery Platform
Uses a fully human antibody library of over 240 billion antibodies, plus synthetic and single-domain libraries, to support discovery of antibody candidates and next-generation therapies.
High-throughput CAR-T Cell Therapy Screening and Optimization Platform
Uses single-cell analysis and next-generation sequencing to screen and optimize CAR-T lead candidates based on phenotypic and functional metrics.
In Vivo CAR-T Platform
Develops in vivo CAR-T products using viral vector engineering, T cell-specific promoters, and proprietary envelope modifications to improve selective T cell transduction and safety.
Advanced Manufacturing and CMC Platform
Provides end-to-end manufacturing and quality systems to support development and commercial-scale production of cell and gene therapy products.
Plasmid Manufacturing
Produces research, GMP-grade, and injectable-grade plasmids using fermentation, purification, in-process analytics, sterilization, and Class A filling.
Lentiviral Vector Manufacturing
Produces lentiviral vectors in a closed, automated, scalable system with batch release testing for identity, potency, sterility, residual DNA, and host-cell protein.
Cell Process Development and Manufacturing
Develops cell products for GMP-compliant manufacturing and supports GMP grade plasmids, viral vectors, and cells.
Clinical Development and Clinical Translational Research Platform
Operates a joint laboratory with a top-tier Chinese hospital to integrate research and clinical development.
1 more services
- Cell product process development and GMP manufacturing
- What to send
- Single intravenous infusion of IASO208
- Patients are not required to undergo conventional apheresis or lymphodepleting conditioning
How to order from Iasobio
What to send, as they list it: Single intravenous infusion of IASO208; Patients are not required to undergo conventional apheresis or lymphodepleting conditioning. They take requests through the contact form on their website. You can contact them directly from this page, or request a quote through Midgard.
Capabilities
- Assays and studies
- Cell therapy
- In vivo
- Antibodies
- Lentivirus
- NGS
- Flow cytometry
12 more
- Process development
- Single-cell analysis
- Next-generation sequencing
- Molecular detection
- Cell function assays
- Identity testing
- Potency testing
- Sterility testing
- Residual DNA testing
- Host-cell protein assays
- Cell function testing
- Host-cell protein testing
- Scale and capacity
- Nanjing Facility: approximately 7,866 square meters GFA
- Shanghai Facility: 32,306 square meters GFA
- Four global R&D and manufacturing sites
- Fully integrated platforms spanning the entire product lifecycle
- Over 240 billion antibodies in the fully human antibody library
- Ten products and product candidates
- Therapeutic areas
- Hematological malignancies
- Autoimmune diseases
- Multiple myeloma
- Relapsed/refractory B-cell non-Hodgkin lymphoma
- B-cell malignancies
- Myasthenia gravis
4 more
- Multiple sclerosis
- Systemic lupus erythematosus
- Lupus nephritis
- B-cell non-Hodgkin lymphoma
Modalities and species
- Modalities
- Antibody
- Bispecific
- mRNA
- Viral vector
- Cell therapy
- Gene editing
- Plasmid DNA
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Scope: cell product process development
Industries served
- Advanced therapy medicinal products
- Cell therapy
- Gene therapy
Company
- Type
- CRDMO
- Founded
- 2017
Locations
- Address
- 1 Xinjinhu Road, Jiangbei New District, Nanjing, Jiangsu Province 210018
- Sites
- Shanghai, China
- Pleasanton, United States
- Pleasanton, CA, United States
- Serves
- China, United States, Singapore, Saudi Arabia, United Arab Emirates, Hong Kong, Japan, Australia, Korea
Contacts
- Phone
- +86 025-58287610